This lecture is intended as a supplementary resource for clinicians and trainees to review evidence and discuss clinical cases.
Separate infection, active disease, infectiousness, and resistance
Resident core · 30–45 minutes with discussion
By the end, decide when to isolate, choose the first diagnostic specimens, recognize the standard treatment pathways, and explain why a positive immune test does not establish active TB. Work through three cases before using the advanced drug, special-population, and trial sections.
Keep four questions separate: has the patient been infected, is there active disease, could they transmit it now, and which drugs are likely to work? One test rarely answers all four.
Protect others while obtaining specimens that can establish the diagnosis
With suspected infectious pulmonary or laryngeal TB, initiate airborne precautions and involve infection prevention and the TB program. Use the institutional pathway for de-isolation; neither a negative IGRA nor one negative respiratory test is a universal clearance rule.
Obtain chest imaging and respiratory specimens for AFB smear and mycobacterial culture, with a TB NAAT on an initial specimen. The usual U.S. collection approach uses three specimens separated by 8–24 hours, including an early-morning specimen. Induced sputum or bronchoscopy may be needed when the patient cannot provide an adequate sample.
AFB smear can support infectiousness assessment but does not identify M. tuberculosis by itself. NAAT can rapidly support TB and, on some platforms, identify resistance markers. A negative NAAT does not exclude all paucibacillary disease. Culture and susceptibility testing remain necessary.
For extrapulmonary disease, sample the involved site and tell the laboratory what is suspected. Plan tissue handling before the biopsy so that the entire specimen is not placed in formalin. In severe illness, do not let a prolonged diagnostic process delay appropriate multidrug treatment.
[5] [29] [6]
Interpret immune tests and mimics in their clinical context
Pulmonary NTM diagnostic criteria
What the result can establish| Finding | Interpretation | Next decision |
|---|
| Positive IGRA or tuberculin skin test | Supports TB infection; does not distinguish latent infection from active disease. | Assess symptoms and imaging, and obtain microbiology when disease is possible before preventive treatment. |
| Negative immune test | Does not exclude active TB, particularly with immunosuppression or recent exposure. | Continue the active-disease evaluation when suspicion remains high. |
| AFB smear positive, TB NAAT negative | Could represent NTM, a testing limitation, or another discordant result. | Review specimen quality and repeat/confirm testing with the laboratory; do not equate every AFB isolate with TB. |
| Cavity or granulomatous pathology | Neither finding is specific for TB. | Consider endemic fungi, NTM, malignancy, bacterial abscess, and inflammatory disease using exposure and host clues. |
In Missouri, histoplasmosis is an important alternative diagnosis. Avoid a “TB versus nothing” differential. A positive NTM culture also needs clinical, radiographic, and microbiologic interpretation before committing to prolonged NTM therapy.
[30] [31] [32] [33]
Standard and shortened treatment for drug-susceptible pulmonary TB
The conventional six-month regimen for drug-susceptible pulmonary TB has an initial two-month phase of isoniazid, rifampin, pyrazinamide and ethambutol, followed by four months of isoniazid and rifampin. Confirmed susceptibility, disease site, response and treatment interruptions determine whether this framework applies. Ethambutol protects the initial regimen while susceptibility is unknown; its withdrawal depends on confirmation of isoniazid and rifampin susceptibility.
The four-month rifapentine-moxifloxacin option is a distinct 17-week, 119-dose regimen for selected pulmonary disease. U.S. eligibility includes age at least 12 years, weight at least 40 kg, component susceptibility and compatible medications. Pregnancy, breastfeeding, prolonged QT risk and most extrapulmonary presentations fall outside routine eligibility. In people with HIV, the evidence supports CD4 counts of at least 100 cells/µL and compatible ART. Shortening the conventional six-month regimen does not reproduce this evidence.
Baseline cavitation together with a positive culture at completion of two months identifies a higher relapse-risk group on conventional treatment; this combination generally supports a seven-month continuation phase, nine months in total. CNS disease, bone or joint disease, pregnancy, hepatic disease and renal failure have additional treatment considerations. A pulmonary shortening study cannot settle those decisions.
Rifampin resistance changes the pathway. Obtain rapid and expanded resistance testing and involve a TB expert. The 2025 U.S. guideline supports six-month BPaLM or BPaL for eligible patients; fluoroquinolone susceptibility, prior drug exposure, and toxicity monitoring determine the choice. The 2026 WHO update also uses disease severity; see
resistant-TB regimens. Never add one drug to a failing regimen.
[2] [4] [7] [1] [37]
Monitor response, toxicity, interactions, and the ability to complete treatment
HIV-associated TB and ART timing
Safety checks during treatment| Issue | Practical action |
|---|
| Hepatic injury | Review baseline risk and liver tests when indicated. New anorexia, nausea, abdominal pain, or jaundice needs prompt assessment; do not simply reassure the patient to finish the drugs. |
| Ethambutol toxicity | Assess baseline visual acuity and color discrimination and ask about vision changes during treatment. Renal impairment changes exposure. |
| Isoniazid neuropathy | Pyridoxine accompanies isoniazid in patients at increased neuropathy risk, including pregnancy, HIV, diabetes, malnutrition, alcohol use disorder and renal failure. |
| Rifamycin interactions | Review ART, anticoagulants, anticonvulsants, transplant drugs, and hormonal contraception. A rifamycin substitution still needs an interaction check. |
| Microbiologic response | Track sputum culture conversion and clinical response. Persistently positive cultures require adherence, absorption, resistance, and source reassessment. |
| Completion | Coordinate public-health reporting, adherence support, medication access, and observed therapy as appropriate. Completion is based on the prescribed doses and permitted time window, not the calendar alone. |
For patients starting ART, the timing depends on CD4 count, TB site and interactions; waiting until all TB treatment is complete is inappropriate. TB meningitis has separate timing guidance. The advanced discussion explains the distinction, including the difference between NIH and ATS/CDC/IDSA guidance.
[2] [36]
Exclude active disease before choosing preventive treatment
Latent TB infection means evidence of infection without active disease. Active TB must be excluded before preventive treatment. Short rifamycin-based courses have favorable completion and safety profiles when eligibility permits: three months of weekly isoniazid-rifapentine, four months of rifampin or three months of isoniazid-rifampin. Their components and durations identify different preventive regimens.
Age, pregnancy, HIV treatment, drug interactions and the presumed source isolate determine eligibility. Isoniazid-only courses remain alternatives when a short regimen is unsuitable. Prevention after drug-resistant exposure requires a separate specialist assessment of the source isolate and the exposed person; routine latent-TB options cannot be assumed active.
Reassess symptoms, adherence, and adverse effects during preventive treatment. Patients should know which symptoms require stopping medication and calling the treating team.
[24] [35]
Use three cases to connect the test result to the next step
Case 1 · The immune test is not the disease diagnosis
An asymptomatic patient has a positive IGRA before starting a TNF inhibitor.
Discuss the next action and the finding that would change it.
Discussion
Assess symptoms and chest imaging and investigate any concern for active disease before selecting preventive treatment. Do not label this active TB from the IGRA alone, and do not begin a preventive regimen while an unexplained pulmonary syndrome is still being evaluated.
Case 2 · A negative result does not close the case
A patient with weight loss, cough, an upper-lobe cavity, and immunosuppression has a negative IGRA.
Discuss the next action and the finding that would change it.
Discussion
Continue airborne precautions and the respiratory microbiologic evaluation. The negative immune test does not rule out active disease. Simultaneously investigate credible mimics and obtain specimens that can distinguish them.
Case 3 · Resistance requires a regimen decision
A respiratory NAAT detects M. tuberculosis and a rifampin-resistance marker.
Discuss the next action and the finding that would change it.
Discussion
Treat the result as urgent. Contact the TB program and an experienced clinician, obtain expanded susceptibility testing, and select a complete active regimen. Do not continue the standard plan unchanged or append a single new drug.
Make the isolation, treatment, and follow-up plans explicit
Hand off the disease site, infectiousness assessment, specimens and resistance results still pending, complete regimen, interaction and toxicity checks, and named public-health and clinical follow-up. Newer trial results belong in the eligible population and care setting described in the study.
End of the resident core. Advanced diagnostic, treatment, and evidence discussions follow.
Advanced teaching and detailed reference begin here
These sections support fellow discussion, additional cases, regimen eligibility and evidence interpretation. They are outside the resident core.
How the host, organism and disease site influence treatment
Active disease, infectiousness, drug resistance and disease site define different clinical questions. Regimen evidence applies to particular populations; eligibility and the ability to monitor toxicity are central to interpreting that evidence.
This module is intended for internal medicine residents, ID fellows and attending physicians. The resident core is designed for 30–45 minutes; evidence details are optional. Cases are fictional teaching examples.
- Separate TB infection from disease and common mimics; select diagnostic tests and infection-prevention actions.
- Explain standard and shortened treatment for drug-susceptible pulmonary TB, including eligibility and reasons for a different course.
- Distinguish BPaLM, BPaL and newer WHO regimens for resistant TB.
- Compare preventive regimens and explain their toxicity, interaction, microbiology and follow-up requirements.
- Critique newer treatment studies using population, comparator, endpoint, effect size and limitations.
Resident pathway
Read the initial approach, diagnostics, mimics, prevention, drug-susceptible and resistant-TB sections, drug monitoring, cases and rounds summary. Be able to explain the regimen and what would change it.
Fellow pathway
Add the evidence review and special-population discussion. Pay particular attention to trial eligibility, the distinction between regimen and strategy trials, resistance mechanisms, and how drug toxicity can weaken a regimen.
Attending review pathway
Start with diagnostic discordance and mimics, then review shortened-regimen eligibility, resistant-TB options, preventive care and the trial tables. Use the cases to ask which finding would change the plan. Allow 30–40 minutes for a focused update or 80–105 minutes for the full primer.
Protect others and establish the diagnosis while planning treatment
The clinical spectrum
Inhaled M. tuberculosis can cause infection without symptoms or evidence of disease. Latent TB infection is not contagious. Progression to disease may follow recent acquisition or occur years later, particularly with impaired immunity. Pulmonary and laryngeal disease drive most transmission; extrapulmonary disease can coexist with an infectious pulmonary focus. Preventive treatment reduces progression from infection to disease. Active disease requires an adequate multidrug combination to achieve cure and limit acquired resistance. [5]
RecognizeSymptoms, exposures, immune status and imaging.
IsolateAirborne precautions when pulmonary or laryngeal TB is suspected.
SampleAFB smear, culture, NAAT and resistance testing.
TreatActive multidrug therapy when indicated.
CoordinateID, infection prevention and public health.
Cough, fever, night sweats, weight loss, hemoptysis or compatible imaging should prompt consideration of TB. Advanced immunosuppression can produce atypical pulmonary findings or disseminated disease. An IGRA or TST measures immune sensitization. It does not distinguish latent infection from disease, establish infectiousness, or exclude active TB when negative. [5] [22]
Obtain three sputum specimens for AFB smear and mycobacterial culture, generally 8-24 hours apart with at least one early-morning specimen. Send a respiratory NAAT on at least one specimen and request rapid molecular resistance testing as appropriate. Induced sputum or bronchoscopy may be needed if adequate sputum cannot be obtained. AFB smear positivity is not specific for M. tuberculosis; culture and organism identification remain necessary. [5]
A positive NAAT can accelerate treatment and public-health action. A negative result does not independently exclude smear-negative TB. Obtain cultures for susceptibility testing and treatment monitoring even when NAAT is positive. If the patient is seriously ill or suspicion is high, obtain specimens promptly and start an appropriate multidrug regimen without waiting weeks for culture. [5] [2]
Airborne precautions are a separate decision
Use an airborne infection isolation room and appropriate respiratory protection. Mask the patient for necessary transport. The traditional CDC hospital pathway includes three negative AFB smears, but its application differs between a patient being evaluated for TB and one with confirmed infectious TB. Confirmed disease also requires assessment of effective treatment and clinical improvement. Persistent suspicion, resistance, or inadequate treatment changes the decision. Follow the current institutional NAAT-based or smear-based pathway with infection prevention; neither one negative test nor a fixed number of treatment days guarantees clearance.
[6]
Notify the local/state TB program promptly for suspected or confirmed disease. Coordinate contact evaluation, reporting and discharge planning. Do not leave the first public-health call until discharge. [7] [6]
Use each diagnostic test to answer the right question
Infection, disease and infectiousness are different questions| Question | Useful evidence | Common mistake |
|---|
| Has infection occurred? | Exposure history plus IGRA or TST in someone for whom testing is indicated. | Calling a positive immune test active TB, or using a negative result to exclude disease. |
|---|
| Is there TB disease now? | Symptoms, examination, imaging and microbiology from the involved site. | Treating an abnormal CT or granulomas as organism identification. |
|---|
| Which drugs will work? | Rapid molecular resistance testing followed by culture-based DST as needed. | Assuming rifampin susceptibility proves susceptibility to every regimen component. |
|---|
| Can this patient transmit TB? | Disease site, respiratory burden, cough, treatment effectiveness and the institutional isolation pathway. | Equating an IGRA result or a single negative sputum test with clearance. |
|---|
A chest radiograph is a starting point; CT can clarify cavities, nodules, adenopathy or a sampling target. Upper-lobe cavitation is suggestive but neither required nor specific. Advanced HIV may produce little cavitation, lower-zone disease or even a deceptively unrevealing radiograph. Imaging cannot reliably distinguish active from healed infection by itself. [5] [22]
Respiratory smear and NAAT: interpret the combination| Smear / NAAT | Interpretation | Next action |
|---|
| Positive / positive | Strong presumptive evidence of pulmonary TB. | Treat and coordinate public health; retain culture and DST. |
|---|
| Positive / negative | NTM becomes more likely; consider assay inhibition or specimen issues. | Discuss with the laboratory, obtain additional specimens and identify the organism. Reassess precautions with IP in clinical context. |
|---|
| Negative / positive | Can support presumptive TB when suspicion is meaningful. | Do not dismiss the NAAT because the smear is negative; obtain cultures and resistance information. |
|---|
| Negative / negative | Does not exclude paucibacillary or smear-negative disease. | Reassess pretest probability, specimen quality and alternative diagnoses; repeat or sample another site when warranted. |
|---|
Prefer induced sputum before bronchoscopy when a patient cannot expectorate or initial expectorated testing is unrevealing. If bronchoscopy is needed, send appropriate BAL specimens and collect post-bronchoscopy sputum. Plan specimen handling with the laboratory before an invasive procedure. [29]
Extrapulmonary disease: sample the involved compartment
Choosing specimens beyond sputum| Presentation | Specimens and complementary tests | Pitfall |
|---|
| Lymphadenopathy or focal tissue lesion | Aspirate or biopsy for mycobacterial culture, NAAT where validated, and histopathology. | Send a fresh sterile portion for microbiology; a specimen entirely in formalin cannot be cultured. |
|---|
| Pleural disease | Pleural fluid cells/chemistry, culture and appropriate molecular testing; consider pleural biopsy if fluid testing is nondiagnostic. | ADA may support the diagnosis in context but is not organism-specific; negative fluid tests do not reliably exclude TB. |
|---|
| Meningitis | CSF opening pressure, cells, glucose/protein, mycobacterial culture and molecular testing; evaluate for other infections. | Low organism burden limits sensitivity. A negative CSF result must not delay treatment when the clinical suspicion is high. |
|---|
| Disseminated, bone/joint or genitourinary disease | Target accessible tissue, aspirate, urine or other involved sites; obtain respiratory specimens if pulmonary involvement is possible. | One negative compartment does not exclude disease elsewhere; alert the laboratory to the suspected diagnosis. |
|---|
Interpret pathology alongside microbiology: necrotizing granulomas raise suspicion but can occur with fungi and NTM; nonnecrotizing granulomas do not rule out TB. Negative extrapulmonary smear, culture or NAAT results are often insufficient to exclude disease. [29] [34]
IGRA and TST: useful for infection, weak shortcuts for disease
IGRA avoids BCG-related false positivity and is generally preferred for BCG-vaccinated people aged at least 5 years. An indeterminate, borderline or invalid result is not a negative test; repeat testing or TST may help after reviewing immune status and collection issues. Recent infection may not yet be detectable: repeat contact testing 8–10 weeks after the last exposure when indicated. Do not order serial IGRAs to demonstrate treatment response. [30]
Read a TST at 48–72 hours, measuring transverse induration rather than redness. Positivity depends on risk: at least 5 mm for HIV, recent close contacts, transplant recipients and major immunosuppression; at least 10 mm for groups such as people born in high-incidence countries, high-risk congregate settings, diabetes and children under 5; at least 15 mm when no risk factors are known. Consult the complete risk list. BCG history does not change these risk-based cutoffs. [31]
For an unexpectedly positive screening test in someone truly at low risk, reconsider why testing was done and use the guideline's confirmatory second-test approach. For high-risk exposure or compatible illness, pursue the relevant infection or disease pathway even when an immune test is negative. [29]
Keep a competing diagnosis until the evidence separates it from TB
Endemic fungal treatment options after diagnosis
A positive IGRA can coexist with cancer, fungal infection or bacterial pneumonia. It does not explain a cavity, lymph node or constitutional syndrome. Ask whether the proposed diagnosis accounts for the time course, immune status, exposures and microbiology.
TB mimics and the next discriminating step| Mimic | Clues that shift the differential | Useful next step |
|---|
| NTM, including MAC and M. kansasii | Structural lung disease, bronchiectasis/nodules or cavities; AFB-positive samples with a negative TB NAAT. | Identify the species and interpret cultures alongside symptoms, imaging and competing diagnoses. Most species require repeated sputum isolation or a qualifying bronchoscopic or biopsy result. One M. kansasii culture can support treatment in a compatible clinical and radiographic syndrome. |
|---|
| Histoplasmosis and other endemic fungi | Geography, travel, soil/bird/bat exposure or immunosuppression; nodules, nodes, cavities or dissemination. | Select fungal antigen, antibody, culture and tissue tests for the syndrome. Histoplasma antigen cross-reacts with Blastomyces; negative early testing may need repetition. |
|---|
| Chronic pulmonary aspergillosis | Pre-existing cavity, chronic symptoms, pleural thickening or a fungal ball. | Aspergillus serology and respiratory testing interpreted with imaging and duration. |
|---|
| Bacterial lung abscess or septic emboli | Aspiration/dental risk, acute toxicity, bacteremia, endocarditis risk or multiple peripheral cavities. | Routine cultures, blood cultures when indicated and evaluation of the relevant anatomic or endovascular source. |
|---|
| Nocardia | Immunosuppression with nodules/cavities; possible CNS dissemination. | Alert microbiology to suspected Nocardia and obtain organism identification; evaluate dissemination as appropriate. |
|---|
| Malignancy | Smoking history, progressive focal lesion, obstruction or persistent adenopathy. | Obtain cytology/tissue when indicated; a positive TB infection test must not close the cancer workup. |
|---|
| GPA or other inflammatory disease | Pulmonary nodules/cavities with ENT, renal or systemic inflammatory findings; sarcoidosis may cause adenopathy/granulomas. | Urinalysis, directed serology and tissue in context. Evaluate infection before escalating immunosuppression. |
|---|
[32] [33] [34]
NTM pulmonary disease generally requires the same species in at least two separately collected sputum cultures, or a qualifying bronchoscopic or biopsy result, alongside compatible illness and imaging and exclusion of alternatives. One M. kansasii culture can carry more weight in a compatible syndrome. Meeting diagnostic criteria does not automatically require treatment. Species, progression and patient priorities inform the decision. Do not apply an empiric TB regimen to all AFB-positive disease. [32]
Attending checkpoint
If the patient is not improving, reconsider the diagnosis before reflexively extending treatment. Review adherence, drug exposure, resistance, a second infection or malignancy, and paradoxical inflammation. Clinical deterioration is a reason to reassess and resample, not proof of either resistance or IRIS.
Six-month therapy remains useful, and selected patients can receive four months
Drug-susceptible treatment choices| Clinical situation | Regimen | Practical interpretation |
|---|
| Usual drug-susceptible pulmonary TB | 2HRZE/4HR | H = isoniazid, R = rifampin, Z = pyrazinamide, E = ethambutol. The initial 2-month phase contains HRZE; the 4-month continuation phase contains HR. Susceptibility and response determine whether this standard framework remains appropriate. |
|---|
| Eligible adolescent or adult with drug-susceptible pulmonary TB | 2HPZM/2HPM, a 17-week course | P = rifapentine, M = moxifloxacin. Initial 8 weeks of HPZM, then 9 weeks of HPM. This changes both the rifamycin and companion drug; it is not four months of RIPE. |
|---|
| Cavitation plus a positive culture at completion of 2 months on the standard regimen | Usually 2HRZE/7HR, 9 months total | Both features together support extension. Review adherence, susceptibility and response rather than extending every cavitary case automatically. |
|---|
| Pyrazinamide omitted or ineffective | Usually a 9-month rifamycin/isoniazid-based course | Initial ethambutol is used while susceptibility is clarified. PZA-resistant disease, including typical M. bovis, needs a revised plan. |
|---|
| Selected child with nonsevere drug-susceptible TB | 2HRZ(E)/2HR, 4 months | A separate pediatric recommendation for ages 3 months to 16 years. Nonsevere criteria and pediatric dosing must be checked; this is not the adult rifapentine-moxifloxacin regimen. |
|---|
[3] [1] [2]
Ethambutol protects the initial regimen while susceptibility is unknown. Its withdrawal depends on confirmed isoniazid and rifampin susceptibility and an otherwise appropriate regimen. Treatment completion reflects the required doses within the permitted time window; elapsed calendar time alone is insufficient. [2]
Eligibility for rifapentine-moxifloxacin
Eligibility includes pulmonary disease, age at least 12 years, weight at least 40 kg, no known or suspected component resistance, and acceptable interaction and QT risk. The 2022 U.S. implementation guidance specified CD4 counts of at least 100 cells/µL and efavirenz-based ART for people with HIV. The current CDC overview describes compatible ART more generally; compatibility still requires a specific interaction assessment for daily rifapentine. Pregnancy, breastfeeding, most extrapulmonary disease and suspected component resistance remain outside routine eligibility. Prior TB therapy or recent fluoroquinolone exposure can change the assessment. [4] [3]
The studied course comprises 119 daily doses with food across the 8-week initial and 9-week continuation phases. Daily rifapentine in this active-disease combination is distinct from weekly rifapentine in 3HP prevention. Pyridoxine accompanies isoniazid in this four-month regimen. Completion requires the full course, follow-up testing, medication access and adherence support. [4] [1]
Why the components cannot be substituted
If the patient cannot receive moxifloxacin, simply removing it from the four-month regimen is not supported. Similarly, stopping standard HRZE/HR at four months because sputum converted early does not reproduce Study 31.
[10]
Rifampin resistance changes the entire regimen
RR-TB means rifampin-resistant TB. MDR-TB is resistant to at least isoniazid and rifampin. Fluoroquinolone susceptibility is a major treatment branch point. Confirm the molecular result, obtain expanded susceptibility testing, review previous TB drugs and contact a TB expert promptly. Never add one drug to a failing regimen. [7] [8]
Short oral regimens for resistant TB| Regimen | Where it fits | What needs checking |
|---|
| BPaLM | Bedaquiline + pretomanid + linezolid + moxifloxacin. U.S. guideline-recommended six-month option for eligible patients aged at least 14 years with rifampin-resistant, fluoroquinolone-susceptible pulmonary TB. | Component activity, prior exposure, interactions, ECG and the ability to monitor linezolid toxicity determine eligibility. Pregnancy, breastfeeding and severe extrapulmonary disease fall outside this U.S. short-regimen population. |
|---|
| BPaL | Bedaquiline + pretomanid + linezolid. U.S. guideline option for eligible patients aged at least 14 years with RR pulmonary TB and fluoroquinolone resistance or intolerance. | Eligibility depends on activity of all three components and the same pregnancy, breastfeeding and severe extrapulmonary exclusions. Prior exposure of at least one month to a component requires expert review and appropriate resistance exclusion. Known or suspected component resistance can invalidate this combination. |
|---|
| BDLLfxC strategy | Bedaquiline + delamanid + linezolid + levofloxacin + clofazimine. WHO six-month alternative for eligible MDR/RR-TB when BPaLM cannot be used. | Susceptibility and disease severity determine the WHO pathway. In the 2026 update, BDLC is limited to nonsevere pulmonary pre-XDR-TB. Age, pregnancy and extrapulmonary disease require the complete WHO eligibility assessment; this pulmonary comparison cannot establish eligibility for those groups. |
|---|
| Nine-month endTB regimens | WHO options include BLMZ, BCLLfxZ and BDLLfxZ for selected fluoroquinolone-susceptible MDR/RR-TB. | Each is a studied combination, not a menu of interchangeable drugs. These are alternatives when six-month regimens are unsuitable; they were not compared directly with BPaLM. |
|---|
| Individualized longer treatment | For resistance, intolerance, disease sites or prior drug exposure that invalidate short-regimen eligibility. | The number and choice of active drugs depend on DST, previous exposure and expert assessment. Duration follows the actual regimen and response; the RR label alone does not determine it. |
|---|
[1] [8] [9] [13] [37]
The September 2026 WHO update separates pulmonary pre-XDR-TB (MDR/RR-TB with additional fluoroquinolone resistance) by severity: BPaL for nonsevere disease and BPaLC, adding clofazimine, for severe disease. WHO advises against BDLC in severe pulmonary pre-XDR-TB because of resistance amplification. The complete WHO eligibility and severity assessment remains necessary with the TB program. These WHO recommendations are distinct from the 2025 U.S. recommendations above. [37]
Abbreviations in resistant-TB combinations: B, bedaquiline; Pa, pretomanid; L, linezolid; M, moxifloxacin; D, delamanid; Lfx, levofloxacin; C, clofazimine; Z, pyrazinamide. These letters name the full combination and do not authorize substitutions.
The 2025 U.S. framework uses 26 weeks of BPaL/BPaLM; the TB-PRACTECAL study evaluated a 24-week regimen. Bedaquiline exposure and linezolid toxicity management are defined within the selected protocol. Drug schedules and toxicity-driven changes from different protocols cannot be combined without reassessing the activity and safety of the whole regimen. [1]
Resistance is more than a rifampin result
Prior bedaquiline/clofazimine or nitroimidazole exposure can affect component activity even when the patient has never received the proposed full combination. Review molecular and phenotypic results with the reference laboratory; the availability and interpretation of newer-drug DST differ from routine antibacterial testing. Loss of linezolid to toxicity can leave too few active companion drugs. Persistent or recurrent culture positivity should prompt renewed DST and adherence/exposure review, not automatic prolongation of the same drugs. [9] [1]
The 2025 U.S. BPaL and BPaLM recommendations describe guideline eligibility. The U.S. pretomanid label covers BPaL in adults with pulmonary TB resistant to isoniazid, rifamycins, a fluoroquinolone, and a second-line injectable, or with pulmonary TB resistant to isoniazid and rifampin who cannot tolerate or have not responded to standard therapy. BPaLM and treatment at ages 14–17 are guideline-supported uses outside the FDA label. The TB program can help reconcile the guideline, label and drug access, including for delamanid-based regimens. [1] [38]
Monitoring should follow the toxicities of the actual regimen
HBV serology · HCV testing and evaluation
Antituberculous drug roles and monitoring| Drug | Role in a regimen | Toxicity and monitoring |
|---|
| Isoniazid | A core drug in the initial and continuation phases of susceptible disease | Hepatotoxicity and peripheral neuropathy. Pyridoxine accompanies treatment when neuropathy risk is increased and is part of the four-month rifapentine-moxifloxacin regimen for all patients. |
|---|
| Rifampin | The rifamycin backbone of conventional susceptible-TB treatment | Major enzyme/transporter induction. Review ART, azoles, anticoagulants, transplant drugs, methadone and hormonal contraception. Orange secretions are expected; jaundice is not. |
|---|
| Pyrazinamide | An initial-phase drug whose omission or resistance changes the conventional course | Hepatotoxicity, arthralgia and hyperuricemia. Asymptomatic hyperuricemia alone is not an indication to stop. Adjust interval in severe renal impairment. |
|---|
| Ethambutol | Initial protection while isoniazid and rifampin susceptibility is being established | Baseline visual acuity and color discrimination, then symptom surveillance and repeat testing according to duration/risk. Stop and evaluate new visual symptoms. Accumulates with renal impairment. |
|---|
| Rifapentine | A rifamycin in the defined 17-week active-disease regimen and in separate preventive regimens | The active-disease regimen uses daily rifapentine with food; 3HP prevention uses weekly rifapentine. The combinations, exposure and treatment purposes are not interchangeable. Interactions require review. |
|---|
| Moxifloxacin / levofloxacin | Fluoroquinolones with different evidence-based combination roles and renal handling | QT, tendinopathy, neuropathy, dysglycemia and cation binding. Correct K+ and Mg2+, assess other QT drugs. Levofloxacin needs renal adjustment. |
|---|
| Bedaquiline | A component of selected resistant-TB combinations with protocol-specific exposure | ECG/QTc, K+, Mg2+, Ca2+, liver tests and interacting drugs. Rifamycins can markedly lower exposure. |
|---|
| Pretomanid | A nitroimidazole used within eligible BPaL-based pulmonary-TB combinations | Hepatic toxicity and combination-regimen adverse effects. Avoid extrapolating pulmonary-trial evidence to CNS disease or pregnancy. |
|---|
| Linezolid | An active companion in selected resistant-TB combinations; prolonged exposure creates substantial toxicity risk | CBC, peripheral neuropathy, vision and symptoms of lactic acidosis. Review serotonergic drugs. Six months is very different from a short antibacterial course. |
|---|
| Delamanid / clofazimine | Components of selected WHO resistant-TB combinations, subject to susceptibility and eligibility | Additive QT risk. Clofazimine can cause skin discoloration and GI toxicity. Monitor the combination, not each drug in isolation. |
|---|
[2] [4] [1] [9]
Baseline and follow-up plan
Document weight, HIV status, pregnancy possibility, complete medication history, prior TB therapy and disease sites. Obtain CBC, creatinine/eGFR, AST/ALT and bilirubin, with hepatitis testing based on risk. Add baseline vision testing for ethambutol or prolonged linezolid and ECG/electrolytes for QT-active regimens. [2] [1]
Follow-up includes symptoms, adherence, weight and toxicity at least monthly. Conventional drug-susceptible pulmonary treatment includes monthly cultures until conversion is documented, including the end-of-intensive-phase specimen. For BPaL/BPaLM, the 2025 guideline’s monitoring table calls for three sputum specimens at baseline and every 1–2 weeks until smear conversion, then one or two every 2 weeks until culture conversion and one monthly through treatment. The accompanying text describes weekly testing until smear conversion. The selected resistant-TB protocol determines the full schedule. Smear or NAAT positivity alone is not proof of viable bacilli or failure. [2] [3] [1]
For prolonged linezolid, check CBC early and frequently, commonly weekly initially, with ongoing neurologic and visual assessment. Use the published regimen-specific ECG and laboratory schedule for BPaL/BPaLM or BDLLfxC. Increase surveillance when renal dysfunction, abnormal baseline results, QT-active combinations or new symptoms raise risk. Therapeutic drug monitoring may help with toxicity, suspected malabsorption or poor response. [1] [9]
New hepatitis needs a same-day plan
Hold hepatotoxic TB drugs and evaluate when ALT is at least 3 times the upper limit of normal with hepatitis symptoms, or at least 5 times without symptoms. Assess bilirubin, INR and other causes. In severe disease, arrange an active nonhepatotoxic interim combination with a TB expert. Reintroduction is supervised and sequential after recovery; do not leave the patient on an accidentally ineffective partial regimen.
[2]
Creatinine clearance below 30 mL/min or hemodialysis changes pyrazinamide and ethambutol handling, generally requiring a longer interval rather than simply a smaller dose. Isoniazid and rifampin usually do not require the same renal adjustment. Dialysis timing, weight and toxicity monitoring remain part of an individualized pharmacy and TB-team assessment. [28] [2]
Disease site and host factors can override the short-course option
Situations requiring a different discussion| Situation | Teaching point |
|---|
| TB meningitis | Treat promptly with a CNS-appropriate multidrug regimen, generally a prolonged course such as 9-12 months. Standard pulmonary shortening trials do not apply. Adjunctive corticosteroids are guideline-supported, but HIV-specific evidence and the 2026 genotype trial require careful interpretation. |
|---|
| Bone, joint or spinal TB | Rifamycin-containing therapy is often 6-9 months; many experts favor 9 months, with longer courses in selected circumstances such as extensive hardware. Assess neurologic compromise, instability, large abscesses and need for tissue diagnosis or surgery. |
|---|
| Pleural or lymph-node TB | Often treatable with a standard six-month course. Enlarging nodes during treatment can be paradoxical, but assess adherence, resistance and other diagnoses before assigning that explanation. |
|---|
| TB and HIV | Coordinate ART and TB treatment together. Do not remove the rifamycin solely to preserve an incompatible ART regimen without expert review. Low CD4 counts and CNS disease affect eligibility and ART timing. |
|---|
| Pregnancy | Treat active disease without delay. U.S. guidance individualizes pyrazinamide use; WHO routinely includes it in standard drug-susceptible treatment. Avoid assuming the rifapentine-moxifloxacin or pretomanid regimens are supported in pregnancy. |
|---|
| Isoniazid resistance with rifampin susceptibility | Do not continue standard HR as if both were active. WHO recommends a six-month rifampin, ethambutol, pyrazinamide and levofloxacin regimen when appropriate susceptibility is established. Check for additional resistance and seek expert input. |
|---|
[2] [22] [23] [8] [21]
For nonpregnant people with HIV starting ART who do not have TB meningitis, NIH places initiation within 2 weeks of starting TB treatment when CD4 is below 50 cells/mm³, and within 2–8 weeks when CD4 is at least 50. During pregnancy, NIH recommends ART initiation as early as feasible regardless of CD4 count; the TB-meningitis safeguards below still apply. For TB meningitis, NIH permits initiation after at least 2 weeks of TB treatment once meningitis is controlled, whereas ATS/CDC/IDSA guidance waits until 8 weeks of TB treatment have been completed. The HIV/TB team therefore needs a documented CNS-specific timing plan. These initiation windows do not instruct patients already taking ART to stop it.[36] [22]
Source control in TB is selective
Antimicrobial therapy is central. Drainage, decompression or surgery is indicated for specific complications, such as neurologic compromise, mechanical instability, selected abscesses or empyema, rather than for every residual lesion. Obtain tissue for histology, mycobacterial culture and DST when diagnosis remains uncertain. Coordinate specimen handling so the only diagnostic sample is not placed entirely in formalin. [2] [5]
Read the endpoint before accepting a shorter treatment claim
Noninferiority means that the confidence interval stayed within a prespecified margin for a specified endpoint in a specified population. It does not establish identical efficacy, prove superiority or show that the regimen works at every disease site. A composite outcome can include loss to follow-up, treatment changes and death as well as microbiologic failure.
Phase 3 RCTStudy 31/A5349 established an eligible four-month option
Among 2,516 randomized participants, the four-month rifapentine-moxifloxacin regimen had unfavorable outcomes in 15.5% versus 14.6% with standard therapy in the microbiologically eligible population. The reported difference was 1.0 percentage point, 95% CI -2.6 to 4.5, within the prespecified noninferiority margin of 6.6 percentage points. The rifapentine regimen without moxifloxacin did not establish noninferiority.
The evidence supports the complete studied combination in eligible pulmonary disease. It does not establish an arbitrary four-month course or remove the trial population restrictions. [10] [4]
Randomized trialTB-PRACTECAL changed the burden of resistant-TB treatment
The 2022 report evaluated 24-week BPaLM against 9-20 months of standard care. Of 301 stage-2 participants, 128 were included in the modified intention-to-treat efficacy population. Unfavorable outcomes at 72 weeks occurred in 11% versus 48%; the risk difference was -37 percentage points, 96.6% CI -53 to -22. Grade 3 or higher or serious adverse events occurred in 19% versus 59%.
Interpretation depends on the comparator, open-label design, early stopping and composite endpoint. This was a major efficacy/tolerability advance over the comparator regimens, but the 37-point difference should not be described as a mortality benefit or as a comparison against every modern oral regimen. [11]
Dose/duration RCTZeNix helped reduce linezolid exposure while preserving activity
ZeNix was a dose-and-duration comparison within bedaquiline-pretomanid treatment. Among 181 participants, the linezolid trial groups were 1,200 mg daily for 26 weeks, 1,200 mg daily for 9 weeks, 600 mg daily for 26 weeks and 600 mg daily for 9 weeks. Favorable outcomes were 93%, 89%, 91% and 84% in that order. In the 600-mg/26-week trial group, peripheral neuropathy occurred in 24% and myelosuppression in 2%.
The comparison informed the lower-exposure approach in current BPaL-based guidance and reinforces the need for toxicity surveillance. These are trial parameters, not a standalone linezolid prescription. ZeNix did not compare BPaL with an external standard-care control, and its four modest-sized groups cannot exclude important efficacy differences. [12] [1]
Phase 3 RCTendTB provided several nine-month alternatives
The trial randomized 754 participants with fluoroquinolone-susceptible RR pulmonary TB; 699 entered the modified intention-to-treat analysis. At week 73, the control favorable-outcome rate was 80.7%. Differences versus control were +9.8 points for BCLLfxZ (95% CI 0.9 to 18.7), +8.3 for BLMZ (-0.8 to 17.4), and +4.6 for BDLLfxZ (-4.9 to 14.1). These three regimens had consistent noninferiority support across analyses, using a 12-point margin.
DCMZ met the modified intention-to-treat criterion but was not supported by the per-protocol analysis. Grade 3 or higher adverse events were common across arms. This trial expands options; it does not establish that nine-month therapy is preferable to BPaLM. [13]
Phase 3 RCT · 2026BEAT-TB supports a pretomanid-free six-month strategy
This pragmatic South African trial randomized 403 participants to six-month bedaquiline, delamanid and linezolid with levofloxacin and/or clofazimine, adjusted to susceptibility, or the local standard strategy. Treatment success sustained through week 76 occurred in 174/202 (86.1%) versus 172/200 (86.0%). The adjusted difference was -0.2 points, 95% CI -6.9 to 6.5, meeting the trial noninferiority criterion.
The study included groups often excluded elsewhere, including pregnancy and people with HIV. Inclusion does not make every subgroup estimate precise. Its comparator was not BPaLM. WHO incorporated the underlying BEAT evidence into 2025 recommendations before this 2026 journal publication. [14] [9]
The next advances must demonstrate durable cure and acceptable toxicity
Investigational strategyTRUNCATE-TB is not routine two-month treatment
The strategy trial included 674 participants in its intention-to-treat population. Initial eight-week bedaquiline-linezolid, with isoniazid, pyrazinamide and ethambutol, was followed by extension for persistent disease, surveillance and retreatment for relapse. At week 96, death, ongoing treatment or active TB occurred in 5.8% versus 3.9% with standard treatment. The adjusted difference was 0.8 points, 97.5% CI -3.4 to 5.1. Mean total treatment time was 85 versus 180 days. [15]
The 2025 regimen analysis used a different question. Unfavorable outcomes, mainly relapse, occurred in 26/189 (14%) on the bedaquiline-linezolid regimen versus 7/181 (4%) with standard therapy; adjusted difference 9.3 points, 95% Bayesian credible interval 4.3 to 14.9. Successful retreatment could rescue the strategy outcome while the initial regimen still had more relapses. Do not present these results as equivalent durable cure after eight weeks. [16]
Phase 2b/c · 2026Quabodepistat offers a new target and a rifamycin-free combination
Quabodepistat inhibits DprE1, a cell-wall synthesis target. A proof-of-concept trial randomized 122 participants with drug-susceptible pulmonary TB to four months of delamanid-bedaquiline-quabodepistat at three dose levels or six months of standard treatment. In the modified intention-to-treat population, end-of-treatment sputum culture conversion was 96/100 (96%) across pooled experimental groups and 21/21 (100%) in control. The difference was -4.0 points, with an 80% CI of -7.4 to 3.4, meeting its 12-point margin.
This is encouraging regimen-development evidence, not proof of equal relapse-free cure. The small control arm, pooled doses, surrogate primary endpoint and 80% rather than 95% interval limit certainty. It does not establish effectiveness in drug-resistant or extrapulmonary TB, and it is not a routine prescribing option. [17]
Phase 2b dose findingSutezolid aims to improve on linezolid's therapeutic window
PanACEA-SUDOCU-01 randomized 75 participants to different sutezolid doses or no sutezolid on a bedaquiline-delamanid-moxifloxacin background. The pharmacokinetic/pharmacodynamic model estimated a 16.7% increase in time-to-positivity slope steepness at exposure typical of 1,200 mg, 95% CI 0.7 to 35.0, relative to no exposure. No neuropathy was reported.
This is a model-based bacteriologic effect, not a 16.7% improvement in cure. The study did not establish a final dose, durable-cure advantage or comparative long-course safety against linezolid. Sutezolid remains a research option. [18]
Phase 2 early activityTelacebec demonstrates activity without establishing a treatment regimen
A 64-patient randomized trial compared three telacebec dose levels with standard four-drug treatment for 14 days. At the highest studied level, the mean daily decline in sputum bacterial load was 0.097 log CFU versus 0.200 with the four-drug control. Activity was dose-dependent and tolerability was favorable during this short observation period.
The study confirms human antimycobacterial activity of an energy-production target. It does not establish monotherapy as treatment, a cure rate, resistance protection or safety over months. Combination studies with relapse follow-up are needed. [19]
Negative phase 3 resultHARVEST did not show a survival benefit from high-dose rifampin in TB meningitis
In 499 adults, adding rifampin to reach 35 mg/kg daily for 8 weeks was compared with 10 mg/kg daily, both within multidrug treatment. Six-month mortality estimates were 44.6% versus 40.7%; hazard ratio 1.17, 95% CI 0.89 to 1.54, P=0.25.
Improved drug exposure is not itself clinical benefit. This trial does not support routine high-dose oral rifampin to improve adult TB-meningitis survival. The interval also does not prove the two strategies equally safe. [20]
Host-directed therapy needs the same evidentiary discipline
In the 2026 genotype-stratified dexamethasone trial in HIV-negative TB meningitis, neither noninferiority nor superiority of placebo was established in the LTA4H CC/CT groups. This does not justify routine genotype-guided steroid omission. Serious adverse events were similar, 52.8% with dexamethasone versus 51.9% with placebo. [21]
For other host-directed agents or long-acting formulations, distinguish preclinical activity, exposure studies and registered trials from demonstrated patient benefit. A proposed anti-inflammatory mechanism or convenient dosing interval is not a reason to add a drug to a standard regimen.
For every new avenue, ask whether it reduces relapse, death, toxicity or treatment burden, and whether resistance was measured. This is a selected evidence review, not an exhaustive inventory of every compound in development. No unpublished cure rates are assumed.
Preventive treatment is a different treatment problem
Exclude active TB before prescribing preventive monotherapy or dual therapy. Symptoms, radiographic abnormalities or significant immunosuppression may require sputum testing even when the referral says “latent TB.” [24]
Common preventive regimens| Regimen | Course | Selection issue |
|---|
| 3HP | Isoniazid + rifapentine weekly for 3 months | CDC option from age 2 years. Check ART interactions. Not recommended during pregnancy or when pregnancy is expected during treatment. |
|---|
| 4R | Rifampin for 4 months | Often useful in HIV-negative adults and children. Check all interacting medications and source-case resistance. |
|---|
| 3HR | Isoniazid + rifampin for 3 months | Option for adults and children, including selected people with HIV when interactions permit. |
|---|
| 6H / 9H | Isoniazid for 6 or 9 months | Alternatives when rifamycin interactions or other constraints preclude short-course therapy; generally less favorable completion and toxicity profiles. |
|---|
| 1HP | Isoniazid + rifapentine daily for 1 month | WHO option, with evidence and age/ART restrictions. It is not the same as 3HP and is not listed as a standard regimen on the CDC general LTBI page. |
|---|
| 6Lfx after MDR/RR-TB exposure | Levofloxacin for 6 months | WHO prevention option after MDR/RR exposure assessment. Active disease must be excluded, and the source-case susceptibility pattern, especially fluoroquinolone resistance, requires TB-program review before eligibility can be established. |
|---|
[24] [26] [25]
The VQUIN and TB-CHAMP pooled analysis combined trials enrolling 2,041 and 922 contacts, respectively. By 54 weeks, TB developed in 8 levofloxacin recipients versus 21 placebo recipients. Low event counts limit precision, and tolerability and adherence remain relevant. This supports a prevention pathway after resistant-TB exposure, not levofloxacin monotherapy for active disease. [27]
Factors that determine preventive-treatment eligibility
Active-disease exclusion comes first. Exposure timing, source-case susceptibility, prior treatment, pregnancy, liver risk and medications then determine preventive-regimen eligibility. Recent contacts and people facing substantial immunosuppression need prompt coordination. Short rifamycin-based regimens generally offer better completion and safety, while interactions can make isoniazid-only treatment the more suitable option. Rifampin plus pyrazinamide is excluded from LTBI regimens because of hepatotoxicity. [35]
Why preventive regimens are not interchangeable| Regimen | Treatment distinction | Eligibility and interaction limits |
|---|
| 3HP | Weekly isoniazid-rifapentine prevention differs from the daily rifapentine combination used for active disease. | Age at least 2 years, compatible medications and no pregnancy or expected pregnancy during the course. Presumed isoniazid or rifampin resistance precludes this option. |
|---|
| 4R | Rifampin alone is a preventive regimen after active disease has been excluded. | Source-case rifampin resistance and interactions can invalidate the choice. HIV treatment may preclude its use. |
|---|
| 3HR | A two-drug preventive course whose purpose and duration differ from active-disease treatment. | Rifampin interactions and source susceptibility remain central, including in people with HIV. |
|---|
| 6H / 9H | Longer isoniazid-only alternatives when short rifamycin-based options are unsuitable. | Hepatotoxicity, neuropathy risk and lower completion remain relevant; avoiding rifamycin interactions does not remove monitoring needs. |
|---|
Age and weight affect pediatric eligibility and exposure. Pyridoxine accompanies isoniazid when neuropathy risk is increased, including pregnancy, HIV, diabetes, malnutrition and renal disease. [24] [2]
Review adherence, new TB symptoms and toxicity monthly. Obtain baseline AST/ALT and bilirubin for hepatic risk, HIV, pregnancy or the first three postpartum months; repeat for abnormal baseline values, ongoing risk or symptoms. Give explicit stop-and-call instructions for hepatitis symptoms, rash, or persistent neuropathy. [24]
Discuss rifamycin interactions with ART, anticoagulants, transplant drugs and contraception before prescribing. Document the infection test, disease-exclusion assessment, regimen, doses completed and completion date. Do not use a repeat IGRA/TST as a cure test. Many pregnant patients can defer prevention until 2–3 months postpartum, but recent exposure or high progression risk can favor treatment during pregnancy. Avoid 3HP during pregnancy; coordinate high-risk decisions with the TB program. [35] [30] [23]
Apply the regimen and evidence to the bedside
Case 1. A negative IGRA is not an exit from the workup
A 47-year-old receiving anti-TNF therapy has 6 weeks of cough, weight loss and an upper-lobe cavity. The IGRA is negative.
Can airborne precautions and the TB evaluation be stopped?
Reason through the decision
No. Continue the disease evaluation and airborne precautions. Collect appropriate respiratory specimens, NAAT and cultures. Immunosuppression can blunt immune-based tests. Decide on empiric multidrug treatment from the full clinical picture, not the IGRA alone. [5] [6]
Case 2. Assessing four-month eligibility
A 28-year-old, 65-kg patient has pulmonary TB with susceptible testing and no extrapulmonary disease. The patient is HIV negative, is not pregnant or breastfeeding, has no relevant drug interactions and has acceptable QT risk.
What is the shorter option, and what is not interchangeable?
Reason through the decision
This profile fits the main population criteria for the 17-week HPZM/HPM option, subject to full TB-program review. The studied course has 8 weeks of HPZM followed by 9 weeks of HPM, with 119 daily doses and structured follow-up. Four months of standard RIPE-based therapy or rifapentine without moxifloxacin does not reproduce the evidence. [4] [10]
Case 3. Cavitation and a positive two-month culture
A patient on standard HRZE had cavitary disease at baseline. The culture obtained at completion of 2 months remains positive and is still drug susceptible.
Is this automatically treatment failure?
Reason through the decision
The two findings identify increased relapse risk; a positive culture at two months alone does not establish treatment failure. Observed doses, interactions, absorption and DST need reassessment. Baseline cavitation plus the positive end-of-two-month culture generally supports a 7-month continuation phase, usually 9 months total, with the TB program. [3] [2]
Case 4. Rifampin resistance is not solved by adding moxifloxacin
A respiratory NAAT detects rifampin resistance. Fluoroquinolone susceptibility is pending.
What information must guide the next regimen?
Reason through the decision
Arrange urgent TB-expert consultation, expanded molecular and phenotypic DST, prior-drug history and an active resistant-TB combination. In the 2025 U.S. framework, FQ susceptibility distinguishes BPaLM from BPaL eligibility; age, pregnancy/breastfeeding, disease site and component resistance can rule out both. The 2026 WHO pulmonary pre-XDR pathway additionally distinguishes disease severity. Do not simply add one drug to HRZE. [7] [1] [37]
Case 5. Linezolid toxicity threatens the combination
During BPaLM therapy, a patient develops falling hemoglobin and new distal tingling. Cultures have converted.
Can linezolid simply be stopped for the remainder?
Reason through the decision
Assess severity and hold or modify the offending drug when clinically necessary, but make the revised regimen with a TB expert. Culture conversion does not eliminate the need for active companion drugs. Check CBC, neurologic findings, visual symptoms, drug exposure and other causes. The duration of prior linezolid and activity of remaining drugs determine the options. [1] [9]
Case 6. An eight-week headline does not establish an eight-week cure
A patient asks for the “two-month TB treatment” after reading about TRUNCATE-TB.
How would you explain the actual evidence?
Reason through the decision
The trial shortened initial treatment and then closely monitored patients, extending or restarting therapy when needed. The later analysis found more unfavorable outcomes with the initial short regimen. It is not a routine alternative to the recommended four- or six-month course. [15] [16]
Case 7. An AFB-positive result without a TB NAAT signal
A 70-year-old with bronchiectasis has chronic cough. The sputum is smear positive but the TB NAAT is negative.
Reason through the decision
No. Consider NTM, specimen or assay issues, and the remaining probability of TB. Ask the laboratory about the discordance, collect additional specimens and await identification/culture. Make the isolation decision with IP; one result does not replace the institutional pathway. If NTM is isolated, assess full disease criteria before treating. [29] [32]
Case 8. A positive IGRA and a growing lung mass
A patient with remote TB exposure has a positive IGRA and an enlarging cavitary lung lesion. Initial sputum studies are unrevealing.
Does the IGRA justify closing the differential?
Reason through the decision
No. Infection testing does not identify the cause of the lesion. Continue a directed TB evaluation and consider tissue for malignancy, fungal infection and other mimics. Coordinate fresh tissue for cultures alongside pathology. [5] [34]
Case 9. Prevention before anti-TNF therapy
An asymptomatic adult has a positive IGRA before anti-TNF treatment, a normal chest radiograph and no evidence of active disease.
What makes a useful LTBI plan?
Reason through the decision
Medication interactions, source resistance and exposure history determine which preventive options are suitable. A complete plan includes monitoring, adherence support and documentation of completion. The timing of immunosuppression requires coordination with the treating team; one interval cannot represent every biologic and clinical urgency. [35] [24]
A useful consult note specifies what happens next
Communicate the disease classification, infectiousness assessment, regimen and its rationale, completed doses, pending resistance results, toxicity plan and person responsible for follow-up. A prescription without an access and follow-up plan is incomplete.
Suspected/confirmed TB at [site], with [microbiology and resistance results].
Airborne precautions [status and criteria to reassess with infection prevention].
Regimen [full drug names, doses, start date and rationale].
Pending tests [culture, molecular and phenotypic DST, other sites].
Monitoring [specific tests, next date and clinician/program reviewing them].
Duration [provisional course and findings that would change it].
Public-health coordination [program, contact and plan for DOT/vDOT].
Discharge [medication supply, follow-up, household risk assessment and transport plan].
Clinical implementation
Confirm current isolation rules, laboratory testing, reporting, TB-program consultation, and drug access with the treating institution. A lecture summary does not establish an isolation decision.
Check that you can explain the decisions
Pause before reading each answer. These are discussion questions for individual study or facilitated teaching.
1. Why should a positive NAAT still be followed by culture?
Answer and rationale
Culture supports organism recovery, susceptibility testing and response assessment. A molecular result does not replace those functions. [5]
2. Which two findings commonly extend the standard pulmonary course to nine months?
Answer and rationale
Baseline cavitation plus a positive sputum culture at completion of two months. Investigate adherence, susceptibility and exposure as part of the same decision. [3]
3. How does daily rifapentine for active TB differ from 3HP?
Answer and rationale
The active-TB regimen uses daily rifapentine within HPZM/HPM for 17 weeks. 3HP uses weekly isoniazid-rifapentine for prevention. Neither the schedules nor the treatment purposes are interchangeable. [4]
4. When does BPaL replace BPaLM in the U.S. guideline?
Answer and rationale
In otherwise eligible rifampin-resistant pulmonary disease with fluoroquinolone resistance or intolerance. Component activity and other eligibility restrictions still apply. [1]
5. What is the response to symptomatic ALT elevation at least three times the upper limit of normal?
Answer and rationale
Hold hepatotoxic drugs and evaluate promptly. Determine severity and an active interim/reintroduction plan with the TB team rather than continuing an ineffective partial regimen. [2]
6. What does the quabodepistat primary endpoint fail to prove?
Answer and rationale
End-of-treatment sputum conversion is not the same as relapse-free cure. A small proof-of-concept study cannot establish effectiveness across disease sites or resistance patterns. [17]
7. Why can the TRUNCATE strategy succeed while its initial regimen has more relapse?
Answer and rationale
The strategy includes detection and retreatment of relapse; successful retreatment can prevent a week-96 strategy failure. That does not erase failure of the initial course. [16]
8. Can a contact with cough and an abnormal radiograph start levofloxacin prevention immediately?
Answer and rationale
Evaluate for active TB first. If disease is present, monotherapy is inappropriate and risks acquired resistance. Source-case DST also informs preventive selection. [25]
9. Does a positive IGRA explain a cavitary lung lesion?
Answer and rationale
No. It supports infection but does not establish the cause of the lesion. Evaluate TB disease and competing diagnoses, with microbiology and tissue when indicated. [5]
10. What must happen before starting 4R for latent infection?
Answer and rationale
Eligibility requires exclusion of active TB and review of source resistance and drug interactions. Counseling, adherence support and monthly follow-up are part of preventive care. Rifampin alone is inappropriate treatment for active TB. [35]
Tuberculosis on rounds
Adult-oriented teaching companion · Edited November 10, 2026 · The full module explains eligibility, evidence and exceptions.
Do not anchor on TB
Consider NTM, endemic fungi, bacterial abscess/emboli, Nocardia, cancer and inflammatory disease. IGRA positivity does not explain a lesion; target culture and tissue.
Preventive treatment
Active disease must be excluded. Short 3HP, 4R or 3HR courses are preferred when eligible; 6H/9H are alternatives. Interactions, source resistance and pregnancy affect selection. Monthly review remains necessary.
Recognize and isolate
Suspected pulmonary/laryngeal TB: airborne precautions, appropriate respirator and prompt IP/TB-program contact. IGRA/TST cannot rule out disease.
Get the right samples
Sputum AFB smear/culture, typically three specimens 8-24 h apart with one early morning; respiratory NAAT and rapid resistance testing. Preserve culture for DST.
Drug-susceptible pulmonary TB
Conventional 2HRZE/4HR; the distinct 17-week HPZM/HPM option requires age ≥12, weight ≥40 kg and compatible drugs. Pregnancy, breastfeeding, most extrapulmonary disease and component resistance preclude routine shortening. HIV eligibility includes CD4 ≥100 and compatible ART.
Reassess duration
On conventional treatment, baseline cavitation plus a positive culture at completion of 2 months generally supports 9 months total after reassessment of doses, DST and exposure. CNS and bone/joint disease have separate duration considerations.
Rifampin-resistant disease
Urgent expert input. U.S. guideline eligibility for BPaLM/BPaL includes age ≥14 and RR pulmonary disease. FQ susceptibility separates the options. The pretomanid label is narrower. Pregnancy, breastfeeding and component resistance can preclude both. U.S. duration is 26 weeks; WHO also distinguishes pulmonary pre-XDR severity. Never add one drug to a failing regimen.
Monitor the combination
At least monthly response/adherence review. Culture frequency follows the regimen; resistant-TB protocols require more frequent early sampling. Liver tests; CBC/neuropathy/vision for linezolid; vision for ethambutol; ECG and K+/Mg2+/Ca2+ for QT-active regimens.
Act on toxicity
Hepatitis symptoms plus ALT ≥3× ULN or ALT ≥5× without symptoms: hold hepatotoxic agents and evaluate. New neuropathy, cytopenia or visual change requires prompt review.
Keep evidence in context
BEAT and endTB expand selected options. Quabodepistat/sutezolid/telacebec remain investigational. TRUNCATE tested surveillance and retreatment, not universal two-month cure.
H isoniazid · R rifampin · Z pyrazinamide · E ethambutol · P rifapentine · M moxifloxacin · B bedaquiline · Pa pretomanid · L linezolid. The full module provides references, eligibility and disease-site qualifications.
Sources and evidence boundaries
Guidelines and original studies are linked below. Numerical trial summaries refer to the populations, comparators and endpoints named in the text. A study result applies within those boundaries.
- ATS/CDC/ERS/IDSA treatment update. 2025. Guideline. Four-month drug-susceptible treatment, pediatric shortening, BPaL/BPaLM and monitoring.
- ATS/CDC/IDSA drug-susceptible TB guideline. 2016. Guideline. Standard treatment, dose adjustment, toxicity, extrapulmonary disease and response assessment.
- CDC treatment of drug-susceptible TB. April 17, 2025. U.S. implementation guidance.
- CDC rifapentine-moxifloxacin implementation guidance. February 25, 2022. Eligibility, exclusions, doses and 119-dose schedule.
- CDC clinical and laboratory diagnosis. Current online guidance. Specimen collection, NAAT, culture and resistance testing.
- CDC prevention of TB transmission in health-care settings. 2005. Hospital airborne precautions. Apply the current institutional implementation policy.
- CDC drug-resistant TB treatment. Current online guidance. U.S. approach to resistant disease and expert consultation.
- WHO consolidated guidelines, module 4, treatment and care. 2025. WHO first edition. See reference 37 for the 2026 second edition. WHO recommendations do not establish U.S. regulatory approval or local availability.
- WHO consolidated operational handbook on tuberculosis, module 4, treatment and care. 2025. Six-month resistant-TB regimens, including BDLLfxC selection, fluoroquinolone-based adjustment, subgroups and duration.
- Dorman et al. Study 31/A5349. 2021. Randomized phase 3 noninferiority trial. Four-month rifapentine regimens with or without moxifloxacin.
- Nyang’wa et al. TB-PRACTECAL. 2022. Randomized trial. A 24-week all-oral regimen for rifampin-resistant TB. Numerical results here refer to the 2022 report.
- Conradie et al. ZeNix. 2022. Randomized linezolid dose/duration trial within BPaL.
- Guglielmetti et al. endTB. January 30, 2025. Randomized phase 3 trial of nine-month oral regimens for fluoroquinolone-susceptible RR-TB.
- Conradie et al. BEAT Tuberculosis. June 25, 2026. Pragmatic randomized phase 3 trial of a six-month strategy for RR-TB.
- Paton et al. TRUNCATE-TB strategy trial. 2023. Randomized strategy trial with extension, monitoring and retreatment.
- Paton et al. TRUNCATE-TB regimen analysis. 2025. Prespecified exploratory analysis of initial eight-week regimens, distinct from the strategy outcome.
- Dawson et al. Quabodepistat-delamanid-bedaquiline. May 29, 2026. Randomized phase 2b/c proof-of-concept study.
- Heinrich et al. PanACEA-SUDOCU-01. Online July 8, 2025. Randomized phase 2b dose-finding study.
- Janssen et al. Telacebec phase 2 trial. 2025. Randomized 14-day early bactericidal activity study.
- Meya et al. HARVEST. December 18, 2025. Randomized trial of high-dose oral rifampin in adult TB meningitis.
- Donovan et al. Genotype-stratified adjunctive dexamethasone. Online January 15, 2026. Randomized phase 3 trial in HIV-negative adults with TB meningitis.
- CDC care for people with TB and HIV. April 17, 2025. HIV-specific treatment considerations and links to NIH guidance.
- CDC TB treatment during pregnancy. Current online guidance. U.S. approach, including individualized pyrazinamide use.
- CDC treatment for latent TB infection. Current online guidance. Preferred short rifamycin-based regimens, exclusions and monitoring.
- WHO preventive treatment guidelines, second edition. 2024, section 1.4. Recommendation for six months of levofloxacin after MDR/RR-TB exposure.
- WHO preventive treatment operational handbook, second edition. 2024, section 5.1. Includes 1HP and comparison of preventive regimens.
- Duong et al. VQUIN and TB-CHAMP individual-participant meta-analysis. Online December 18, 2024. Randomized preventive-treatment evidence in household contacts, distinct from active-TB treatment.
- WHO treatment and care operational handbook. 2025, chapter 1, section 8, drug-susceptible TB in special situations. Renal and hepatic considerations; used here for renal dosing and monitoring.
- ATS/CDC/IDSA diagnosis of TB in adults and children. 2017. Diagnostic guideline: discordant results, specimen selection and interpretation.
- CDC IGRA clinical testing guidance. Current online guidance. Immune-test interpretation, limitations and repeat testing.
- CDC tuberculin skin testing guidance. Current online guidance. Reading and risk-based thresholds.
- ATS/ERS/ESCMID/IDSA NTM pulmonary disease guideline. 2020. Distinguishing NTM isolation from pulmonary disease.
- CDC histoplasmosis testing algorithm. May 13, 2024. Endemic fungal testing and antigen/antibody limitations.
- Gadkowski and Stout. Cavitary pulmonary disease. 2008. Background differential diagnosis; not used for current treatment recommendations.
- NTCA/CDC latent TB treatment recommendations. 2020. Regimen selection, benefits, interactions and toxicity.
- NIH adult and adolescent OI guidance, Mycobacterium tuberculosis. Updated May 2, 2024; reviewed by NIH March 16, 2026. ART timing and TB/HIV interactions. NIH adult and adolescent ARV guidance, TB/HIV coinfection. Updated and reviewed September 12, 2024. ART timing during pregnancy and continuation of established ART.
- WHO consolidated guidelines on tuberculosis, module 4, second edition. September 25, 2026. WHO issuing update, September 30, 2026. Severity-specific pulmonary pre-XDR-TB recommendations.
- Pretomanid U.S. prescribing information. Section 1, FDA-labeled limited population and combination.